Study Title | A Phase 1/2 Study of Tiragolumab and Atezolizumab in Patients with Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors |
---|---|
Protocol ID | PEPN2121 |
Disease (Sub Disease) | Multiple tumour types |
Diagnosis Stage | Newly diagnosed Relapsed/Refractory |
Sponsor | National Cancer Institute (NCI) |
Links | https://clinicaltrials.gov/ct2/show/NCT05286801 |
Trial Status | Preparing to Open |
Study Type | Treatment |
Phase | Phase 1/2 |
Age Eligibility | 12 Months and older |
International registry ID's | NCT05286801 |